Diabetic neuropathy: clinical manifestations and current treatments
Summary Diabetic peripheral neuropathy is a prevalent, disabling disorder. The most common manifestation is distal symmetrical polyneuropathy (DSP), but many patterns of nerve injury can occur. Currently, the only effective treatments are glucose control and pain management. While glucose control su...
Gespeichert in:
| Veröffentlicht in: | Lancet neurology 2012-06, Vol.11 (6), p.521-534 |
|---|---|
| Hauptverfasser: | , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 534 |
|---|---|
| container_issue | 6 |
| container_start_page | 521 |
| container_title | Lancet neurology |
| container_volume | 11 |
| creator | Callaghan, Brian C, Dr Cheng, Hsinlin T, MD Stables, Catherine L, PhD Smith, Andrea L, MS Feldman, Eva L, Prof |
| description | Summary Diabetic peripheral neuropathy is a prevalent, disabling disorder. The most common manifestation is distal symmetrical polyneuropathy (DSP), but many patterns of nerve injury can occur. Currently, the only effective treatments are glucose control and pain management. While glucose control substantially decreases the development of neuropathy in those with type 1 diabetes, the effect is probably much smaller in those with type 2 diabetes. Evidence supports the use of specific anticonvulsants and antidepressants for pain management in patients with diabetic peripheral neuropathy. However, the lack of disease-modifying therapies for diabetic DSP makes the identification of new modifiable risk factors essential. Growing evidence supports an association between components of the metabolic syndrome, including prediabetes, and neuropathy. Studies are needed to further explore this association, which has implications for the development of new treatments for this common disorder. |
| doi_str_mv | 10.1016/S1474-4422(12)70065-0 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4254767</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1474442212700650</els_id><sourcerecordid>2666817081</sourcerecordid><originalsourceid>FETCH-LOGICAL-c701t-7cf2239135d88217922bc1626010a5a0acb4725a30f2073976760008f92bfd9d3</originalsourceid><addsrcrecordid>eNqNkU1v1DAQhi0Eoh_wE0CRuJRDYDxx7IRDEdpCQarEoeVsOY5DXRJ7azuV9t_j_egWeoGTLfvxM555CXlF4R0Fyt9fUiZYyRjiCcW3AoDXJTwhh7tjXj_d7xEPyFGMNwBIWUOfkwNEDg3n_JAszqzqTLK6cGYOfqnS9epDoUfrrFZjMSlnBxOTSta7WCjXF3oOwbhUpGBUmvIuviDPBjVG83K3HpMfXz5fLb6WF9_Pvy0-XZRaAE2l0ANi1dKq7psGqWgRO015_goFVStQumMCa1XBgCCqVnDBAaAZWuyGvu2rY3K69S7nbjK9zrWDGuUy2EmFlfTKyr9vnL2WP_2dZFizbMuCk50g-Ns5tyUnG7UZR-WMn6OkUOX5cCGq_0BpjUxAgxl98wi98XNweRIbivJ1Npmqt5QOPsZghv2_Kaw5LjeJynVckqLcJCohv3v9Z9P7V_cRZuDjFjB59HfWBBm1NU6b3gajk-y9_WeJ00eG-_x_mZWJD93IiBK2krWD4sYA1W-ztMOJ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1015160065</pqid></control><display><type>article</type><title>Diabetic neuropathy: clinical manifestations and current treatments</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Callaghan, Brian C, Dr ; Cheng, Hsinlin T, MD ; Stables, Catherine L, PhD ; Smith, Andrea L, MS ; Feldman, Eva L, Prof</creator><creatorcontrib>Callaghan, Brian C, Dr ; Cheng, Hsinlin T, MD ; Stables, Catherine L, PhD ; Smith, Andrea L, MS ; Feldman, Eva L, Prof</creatorcontrib><description>Summary Diabetic peripheral neuropathy is a prevalent, disabling disorder. The most common manifestation is distal symmetrical polyneuropathy (DSP), but many patterns of nerve injury can occur. Currently, the only effective treatments are glucose control and pain management. While glucose control substantially decreases the development of neuropathy in those with type 1 diabetes, the effect is probably much smaller in those with type 2 diabetes. Evidence supports the use of specific anticonvulsants and antidepressants for pain management in patients with diabetic peripheral neuropathy. However, the lack of disease-modifying therapies for diabetic DSP makes the identification of new modifiable risk factors essential. Growing evidence supports an association between components of the metabolic syndrome, including prediabetes, and neuropathy. Studies are needed to further explore this association, which has implications for the development of new treatments for this common disorder.</description><identifier>ISSN: 1474-4422</identifier><identifier>EISSN: 1474-4465</identifier><identifier>DOI: 10.1016/S1474-4422(12)70065-0</identifier><identifier>PMID: 22608666</identifier><identifier>CODEN: LANCAO</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Anticonvulsants ; Antidepressants ; Diabetes ; Diabetes mellitus ; Diabetic Neuropathies - drug therapy ; Diabetic Neuropathies - physiopathology ; Diabetic Neuropathies - therapy ; Diabetic neuropathy ; Glucose ; Humans ; Injuries ; Ischemia ; Metabolic disorders ; Metabolic syndrome ; Nerves ; Nervous system ; Neurology ; Pain ; Pain management ; Patients ; Peripheral neuropathy ; Polyneuropathy ; Quality of life ; Risk Factors</subject><ispartof>Lancet neurology, 2012-06, Vol.11 (6), p.521-534</ispartof><rights>Elsevier Ltd</rights><rights>2012 Elsevier Ltd</rights><rights>Copyright © 2012 Elsevier Ltd. All rights reserved.</rights><rights>Copyright Elsevier Limited Jun 2012</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c701t-7cf2239135d88217922bc1626010a5a0acb4725a30f2073976760008f92bfd9d3</citedby><cites>FETCH-LOGICAL-c701t-7cf2239135d88217922bc1626010a5a0acb4725a30f2073976760008f92bfd9d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1474442212700650$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,776,780,881,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/22608666$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Callaghan, Brian C, Dr</creatorcontrib><creatorcontrib>Cheng, Hsinlin T, MD</creatorcontrib><creatorcontrib>Stables, Catherine L, PhD</creatorcontrib><creatorcontrib>Smith, Andrea L, MS</creatorcontrib><creatorcontrib>Feldman, Eva L, Prof</creatorcontrib><title>Diabetic neuropathy: clinical manifestations and current treatments</title><title>Lancet neurology</title><addtitle>Lancet Neurol</addtitle><description>Summary Diabetic peripheral neuropathy is a prevalent, disabling disorder. The most common manifestation is distal symmetrical polyneuropathy (DSP), but many patterns of nerve injury can occur. Currently, the only effective treatments are glucose control and pain management. While glucose control substantially decreases the development of neuropathy in those with type 1 diabetes, the effect is probably much smaller in those with type 2 diabetes. Evidence supports the use of specific anticonvulsants and antidepressants for pain management in patients with diabetic peripheral neuropathy. However, the lack of disease-modifying therapies for diabetic DSP makes the identification of new modifiable risk factors essential. Growing evidence supports an association between components of the metabolic syndrome, including prediabetes, and neuropathy. Studies are needed to further explore this association, which has implications for the development of new treatments for this common disorder.</description><subject>Anticonvulsants</subject><subject>Antidepressants</subject><subject>Diabetes</subject><subject>Diabetes mellitus</subject><subject>Diabetic Neuropathies - drug therapy</subject><subject>Diabetic Neuropathies - physiopathology</subject><subject>Diabetic Neuropathies - therapy</subject><subject>Diabetic neuropathy</subject><subject>Glucose</subject><subject>Humans</subject><subject>Injuries</subject><subject>Ischemia</subject><subject>Metabolic disorders</subject><subject>Metabolic syndrome</subject><subject>Nerves</subject><subject>Nervous system</subject><subject>Neurology</subject><subject>Pain</subject><subject>Pain management</subject><subject>Patients</subject><subject>Peripheral neuropathy</subject><subject>Polyneuropathy</subject><subject>Quality of life</subject><subject>Risk Factors</subject><issn>1474-4422</issn><issn>1474-4465</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2012</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqNkU1v1DAQhi0Eoh_wE0CRuJRDYDxx7IRDEdpCQarEoeVsOY5DXRJ7azuV9t_j_egWeoGTLfvxM555CXlF4R0Fyt9fUiZYyRjiCcW3AoDXJTwhh7tjXj_d7xEPyFGMNwBIWUOfkwNEDg3n_JAszqzqTLK6cGYOfqnS9epDoUfrrFZjMSlnBxOTSta7WCjXF3oOwbhUpGBUmvIuviDPBjVG83K3HpMfXz5fLb6WF9_Pvy0-XZRaAE2l0ANi1dKq7psGqWgRO015_goFVStQumMCa1XBgCCqVnDBAaAZWuyGvu2rY3K69S7nbjK9zrWDGuUy2EmFlfTKyr9vnL2WP_2dZFizbMuCk50g-Ns5tyUnG7UZR-WMn6OkUOX5cCGq_0BpjUxAgxl98wi98XNweRIbivJ1Npmqt5QOPsZghv2_Kaw5LjeJynVckqLcJCohv3v9Z9P7V_cRZuDjFjB59HfWBBm1NU6b3gajk-y9_WeJ00eG-_x_mZWJD93IiBK2krWD4sYA1W-ztMOJ</recordid><startdate>20120601</startdate><enddate>20120601</enddate><creator>Callaghan, Brian C, Dr</creator><creator>Cheng, Hsinlin T, MD</creator><creator>Stables, Catherine L, PhD</creator><creator>Smith, Andrea L, MS</creator><creator>Feldman, Eva L, Prof</creator><general>Elsevier Ltd</general><general>Elsevier Limited</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0TZ</scope><scope>3V.</scope><scope>7RV</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>88G</scope><scope>8AO</scope><scope>8C2</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M1P</scope><scope>M2M</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>PSYQQ</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20120601</creationdate><title>Diabetic neuropathy: clinical manifestations and current treatments</title><author>Callaghan, Brian C, Dr ; Cheng, Hsinlin T, MD ; Stables, Catherine L, PhD ; Smith, Andrea L, MS ; Feldman, Eva L, Prof</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c701t-7cf2239135d88217922bc1626010a5a0acb4725a30f2073976760008f92bfd9d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2012</creationdate><topic>Anticonvulsants</topic><topic>Antidepressants</topic><topic>Diabetes</topic><topic>Diabetes mellitus</topic><topic>Diabetic Neuropathies - drug therapy</topic><topic>Diabetic Neuropathies - physiopathology</topic><topic>Diabetic Neuropathies - therapy</topic><topic>Diabetic neuropathy</topic><topic>Glucose</topic><topic>Humans</topic><topic>Injuries</topic><topic>Ischemia</topic><topic>Metabolic disorders</topic><topic>Metabolic syndrome</topic><topic>Nerves</topic><topic>Nervous system</topic><topic>Neurology</topic><topic>Pain</topic><topic>Pain management</topic><topic>Patients</topic><topic>Peripheral neuropathy</topic><topic>Polyneuropathy</topic><topic>Quality of life</topic><topic>Risk Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Callaghan, Brian C, Dr</creatorcontrib><creatorcontrib>Cheng, Hsinlin T, MD</creatorcontrib><creatorcontrib>Stables, Catherine L, PhD</creatorcontrib><creatorcontrib>Smith, Andrea L, MS</creatorcontrib><creatorcontrib>Feldman, Eva L, Prof</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Pharma and Biotech Premium PRO</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Psychology Database (Alumni)</collection><collection>ProQuest Pharma Collection</collection><collection>Lancet Titles</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest Psychology</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest One Psychology</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Lancet neurology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Callaghan, Brian C, Dr</au><au>Cheng, Hsinlin T, MD</au><au>Stables, Catherine L, PhD</au><au>Smith, Andrea L, MS</au><au>Feldman, Eva L, Prof</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Diabetic neuropathy: clinical manifestations and current treatments</atitle><jtitle>Lancet neurology</jtitle><addtitle>Lancet Neurol</addtitle><date>2012-06-01</date><risdate>2012</risdate><volume>11</volume><issue>6</issue><spage>521</spage><epage>534</epage><pages>521-534</pages><issn>1474-4422</issn><eissn>1474-4465</eissn><coden>LANCAO</coden><abstract>Summary Diabetic peripheral neuropathy is a prevalent, disabling disorder. The most common manifestation is distal symmetrical polyneuropathy (DSP), but many patterns of nerve injury can occur. Currently, the only effective treatments are glucose control and pain management. While glucose control substantially decreases the development of neuropathy in those with type 1 diabetes, the effect is probably much smaller in those with type 2 diabetes. Evidence supports the use of specific anticonvulsants and antidepressants for pain management in patients with diabetic peripheral neuropathy. However, the lack of disease-modifying therapies for diabetic DSP makes the identification of new modifiable risk factors essential. Growing evidence supports an association between components of the metabolic syndrome, including prediabetes, and neuropathy. Studies are needed to further explore this association, which has implications for the development of new treatments for this common disorder.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>22608666</pmid><doi>10.1016/S1474-4422(12)70065-0</doi><tpages>14</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1474-4422 |
| ispartof | Lancet neurology, 2012-06, Vol.11 (6), p.521-534 |
| issn | 1474-4422 1474-4465 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4254767 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Anticonvulsants Antidepressants Diabetes Diabetes mellitus Diabetic Neuropathies - drug therapy Diabetic Neuropathies - physiopathology Diabetic Neuropathies - therapy Diabetic neuropathy Glucose Humans Injuries Ischemia Metabolic disorders Metabolic syndrome Nerves Nervous system Neurology Pain Pain management Patients Peripheral neuropathy Polyneuropathy Quality of life Risk Factors |
| title | Diabetic neuropathy: clinical manifestations and current treatments |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T00%3A28%3A02IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Diabetic%20neuropathy:%20clinical%20manifestations%20and%20current%20treatments&rft.jtitle=Lancet%20neurology&rft.au=Callaghan,%20Brian%20C,%20Dr&rft.date=2012-06-01&rft.volume=11&rft.issue=6&rft.spage=521&rft.epage=534&rft.pages=521-534&rft.issn=1474-4422&rft.eissn=1474-4465&rft.coden=LANCAO&rft_id=info:doi/10.1016/S1474-4422(12)70065-0&rft_dat=%3Cproquest_pubme%3E2666817081%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1015160065&rft_id=info:pmid/22608666&rft_els_id=S1474442212700650&rfr_iscdi=true |